Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

from date of second-line treatment initiation until progression by RECIST1.1 criteria, or death

the date of second-line treatment initiation until death from any cause(only for patients receiving 2L CT and 2L TKI, separately)

Time to initiate second line therapy from RECIST1.1 defined progression from 1L treatment

Response rate reported by physician or judged by Recist1.1 after receiving any pattern of therapy

For each line of chemotherapy received but not limited in:Therapy regimen，Therapy duration measured as time from therapy start date to time of therapy end date，Number of cycles received，Reason for cessation of therapy

For each line of immunotherapy received but not limited in:Therapy regimen，Therapy duration measured as time from therapy start date to time of therapy end date，Number of cycles received，Reason for cessation of therapy

For each line of targeted therapy received but not limited in:Therapy regimen，Therapy duration measured as time from therapy start date to time of therapy end date，Number of cycles received，Reason for cessation of therapy

For each line of local therapy received but not limited in:Therapy regimen，Therapy duration measured as time from therapy start date to time of therapy end date，Number of cycles received，Reason for cessation of therapy

Any palliative/supportive care received

To estimate parameters in the target population associated with molecular testing patterns, including molecular testing sample type

To estimate parameters in the target population associated with molecular testing patterns, including molecular test outcome

To estimate parameters associated with molecular testing patterns, including changes in testing rate over time

Molecular testing rate defined as the number of patients identified as having received molecular testing divided by the number of patients

Time from the RECIST defined progression date to molecular testing

To estimate parameters in the target population associated with molecular testing patterns, including molecular testing method of biopsy

To estimate parameters in the target population associated with molecular testing patterns, including molecular testing turnaround time

To estimate parameters in the target population associated with molecular testing patterns, including molecular test type

To estimate parameters in the target population associated with molecular testing patterns, including reason for molecular testing

To estimate parameters in the target population associated with molecular testing patterns, including molecular testing laboratory type

To estimate parameters in the target population associated with molecular testing patterns including reason for not performing a molecular test

To estimate parameters in the target population associated with molecular testing patterns including molecular testing result of mutation status

To estimate parameters in the target population associated with molecular testing patterns, including molecular result of mutation type

To estimate parameters in the target population associated with molecular testing patterns, including histologic/phenotypic transformation

Overall CNS metastases rate, defined as the number of patients developing CNS metastases divided by the number of evaluable patients (From start of 2L therapy)

Brain metastases rate, defined as the number of patients developing brain metastases divided by the number of evaluable patients

Leptomeningeal metastases rate, defined as the number of patients developing leptomeningeal metastases divided by the number of evaluable patients

Treatments for CNS metastases, including type of treatment

Treatments for CNS metastases, including dates of treatment

To assess patient-reported HRQoL using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 items (EORTC QLQ-LC13)

To assess patient-reported HRQoL using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 items (EORTC QLQ-LC13)